Comparative functional analysis of interstitial versus Langerhans dendritic cells in a human cell line model 119
Introduction
Dendritic cells (DC) are professional antigen presenting cells (APC) with the unique ability to initiate primary T cell responses (1) (2) (3) . Myeloid DC differentiate from CD34+ hematopoietic progenitor cells (HPC) and can develop into two recognized subsets, Langerhans cells (LC), which are mostly found in the epidermis, and Interstitial DC (IDC), which are mostly located in connective tissues (4, 5) .
Because of their critical role in orchestrating the immune response, DC have been used as a cellular adjuvant in immunotherapy of cancer. Numerous animal studies have shown that administration of tumor-antigen loaded DC could induce protective immunity in naive animals (6) (7) (8) , as well as tumor regression and tumor-free survival in mice bearing established tumors (9) . The immunogenicity of DC has also been shown in human clinical trials. Initially, DC vaccination studies were performed with DC directly isolated from peripheral blood (10, 11) . Major disadvantages of this approach were the low yields of DC (11) , the variety of peripheral blood DC subsets (12) (13) (14) (15) (16) .
So far, in the vast majority of clinical trials MoDC have been used for vaccination, while only few trials have made use of CD34-DC (as reviewed by Davis et al. (17) ). However, it has been suggested that CD34-DC are more effective as compared to MoDC in clinical DC vaccination studies (15) , as well as in in vitro antigen-specific T cell stimulation (18) . The beneficial effect of these CD34-DC might be due to the presence of "contaminating" LC in the CD34-DC preparations. This hypothesis was supported by Ratzinger and co-workers, demonstrating that CD34-LC exhibit a superior capacity to induce influenzavirus-and tumor-specific CTL in vitro, compared to MoDC and CD34-DC (both belonging to the IDC subset) (19) . For clinical DC vaccination purposes however, functional differences between IDC and LC remain to be characterized more extensively, not only at the level of T cell priming, but also for their capacity to migrate towards lymph nodes and their ability to release T cell-stimulatory cytokines and skew Th1/Th2 cytokine profiles. Such extensive comparative studies are hampered by difficulties in the generation of large amounts of Birbeck granule-containing, Langerin+ LC. We have previously shown that DC-SIGN+ IDC and bona fide Langerin+/Birbeck granule+ LC can be generated from the MUTZ-3 cell line, a human CD34+ acute myeloid leukemia cell line (20, 21) . In addition, we observed equivalent in vitro T cell priming efficiencies for autologous MoDC and MUTZ-3 IDC, matched for HLA-A2 or -A3 expression, both generating functional tumor-specific CTL (22) .
These observations indicate the validity of the MUTZ-3 cell line model, which facilitates extensive head-to-head comparative functional studies of IDC versus LC.
In the current study we characterized functional properties crucial for the in vivo generation of CTL-mediated immunity of MUTZ3-derived IDC and LC. Our data show that both DC subsets are capable of tumor-specific CTL induction. However, T cell priming efficiency of IDC was superior compared to LC, most likely due to the inability of LC to release type-1 T cell-stimulatory cytokines.
Indeed, transduction with IL-12p70 significantly enhanced the CTL priming efficiency of LC and ensured a functional equivalence with IDC in this regard. We conclude that both DC subsets are valid vaccine vehicles for tumor immunotherapy, but that provision of type-1 T cell stimulatory cytokines such as IL-12p70 is required to ensure optimal T cell stimulation, particularly by LC.
Materials and Methods

Cell Lines
The human CD34+ acute myeloid leukemia cell line MUTZ-3 (Deutsche Sammlung von Mikroorganismen und Zellkulturen [DSMZ], Braunschweig, Germany) was cultured as described previously (20, 22) . The EBV-transformed B cell line JY and the TAP-deficient cell line T2 (both HLA-A2+) were cultured in IMDM (BioWhittaker, Verviers, Belgium) supplemented with 10 % fetal bovine serum (Perbio, Helsingborg, Sweden), 100 I.E./ml sodium penicillin (Yamanouchi Pharma, Leiderdorp, The Netherlands), 100 μg/ml streptomycin sulphate (Radiumfarma-Fisiopharma, Naples, Italy), 2.0 mM L-glutamine (Invitrogen, Breda, The Netherlands) and 0.01 mM 2-mercapoethanol (Merck, Darmstadt, Germany) (i.e. complete medium). The prostate cancer cell line PC-3, the colon carcinoma cell line SW620, the glioblastoma cell line U251 and the melanoma cell lines Mel-JKO and Mel-AKR were cultured in DMEM complete medium.
Synthetic Peptides
The HLA-A2-restricted peptides CEA 571-579 (YLSGANLNL), PSA 146-154 (KLQCVDLHV), Her-2/neu 369-377 (KIFGSLAFL), MART-1 26-35L (ALGIGILTV) and Bcr-abl 926-934 (SSKALQRPV) were synthesized by solid-phase strategies on an automated multiple peptide synthesizer (Syro II, MultiSyntech, Witten, Germany) using Fmoc-chemistry. Peptides were analyzed by reversed-phase high performance liquid chromatography (HPLC), dissolved in DMSO (Merck) and stored at -20ºC.
Retroviral IL-12p70 transduction of MUTZ-3
The IL-12elasti cassette containing the p35 and p40 subunits of IL-12 joined together by a flexible linker (InvivoGen, San Diego, CA) was introduced into MUTZ-3 cells by retroviral transduction. The truncated, signaling defective form of the Nerve growth factor receptor (ΔNGFR) was used as a marker gene for transduced cells. The retroviral vector LZRS-IL-12-IRES-ΔNGFR, constructed by replacing the hTERT ORF from the LZRS-hTERT-IRES-ΔNGFR construct (23) with the IL-12elasti cassette, was used to produce the retroviral supernatant. Retroviral transduction of MUTZ-3 was performed as described previously (24) . Briefly, 5 x 10 5 MUTZ-3 cells, were resuspended in retroviral supernatant supplemented with 10% 5367 conditioned medium and transferred to a fibronectin (RetroNectin; Takara, Otsu, Japan)-coated well of a non-tissue-culture-treated 24-well plate (BD Biosciences). Plates were centrifuged, followed by 5-h incubation at 37°C. The next day, retroviral transduction was repeated. A NGFR-specific antibody (Chromoprobe, Aptos, CA) was used to analyze transduction efficiency and isolate transduced cells by flow sorting.
In vitro Generation of Monocyte-Derived and MUTZ-3-Derived Interstitial and Langerhans-like
Dendritic Cells
MoDC, MUTZ-3 IDC, MUTZ-3-LC and MUTZ-3-IL-12-derived IDC and LC (hereafter referred to as MUTZ-3-IL-12 IDC and LC), were generated as described (20, 21, 25) . At day 7 or day 10, maturation of MoDC, MUTZ-3 IDC and LC was induced by adding a cytokine cocktail consisting of 50 ng/ml TNF-α, 100 ng/ml IL-6, 25 ng/ml IL-1β (hereafter referred to as MCM mimic; Strathmann Biotec, Hamburg, Germany), with or without 1 μg/ml PGE2 (Sigma-Aldrich, St. Louise, MO) or by adding a type-1-polarizing cytokine cocktail containing 50 ng/ml TNF-α, 25 ng/ml IL-1β, 1000 U/ml IFN-γ, 20 μg/ml poly-I:C (Sigma) and 3000 U/ml IFN-α (Peprotech, London, UK) (hereafter referred to as IFNα/p-I:C type-1 cytokine cocktail (26) ).
Antibodies, Tetramers and Flow Cytometry
PE-or FITC-labeled Abs directed against human CD34 (Strathmann Biotec), CD40, CD83, CD8β, Langerin, TCRαβ, TCRγδ (Immunotech, Marseille, France), CD1a, CD8α, CD14, CD28, CD27, CD45RA, CD54RO, CD54, CD62L, CD80, CD86, CCR7 (2H4), DC-SIGN, HLA-DR (all from BD Biosciences, Mountain view, CA) were used for flow cytometric analysis. PE-and/or APC-labeled HLA-A2 tetramers (Tm) presenting the CEA 571 , PSA 146 , MART-1 26L and Her-2/neu 369 epitopes were prepared as described previously (27) . Antibody and/or tetramer staining was performed in PBS supplemented with 0.1% BSA and 0.02% natrium-azide for 30 minutes at 4ºC and 15 minutes at 37 ºC respectively. Stained cells were analyzed on a FACScalibur (BD Biosciences) using Cell Quest software. To exclude dead cells in flow cytometric tetramer analysis, 0.5 μg/ml propidium iodide (ICN Biomedicals, Zoetermeer, The Netherlands) was used.
Primary CTL Induction in vitro
Antigen-specific CD8+ T cells were generated as described, with some minor modifications (22, 23) . In brief, mature MUTZ-3 IDC and MUTZ-3 LC, either derived from wild-type MUTZ-3 or IL-12transfected MUTZ-3, were loaded with 1 μg/ml peptide in the presence of 3 μg/ml β2-microglobulin (Sigma-Aldrich, St. Louise, MO) for 2-4 hours at room temperature and irradiated (40 Gy). 1x10 5 peptide-loaded DC were cultured for 10 days with 1x10 6 CD8β+ CD8+ T precursors and 1x10 6 irradiated (80 Gy) CD8βautologous PBMC in Yssel's medium (28) supplemented with 1% hAB serum (ICN Biochemicals), 10 ng/ml IL-6 and 10 ng/ml IL-12 (in experiments with wild-type MUTZ-3 IDC/LC) in a 24 well tissue-culture plate. At day 1, 10 ng/ml IL-10 (R&D Systems, Minneapolis, MN) was added. After 10 days, CD8+ T cell cultures were re-stimulated with 1x10 5 fresh MUTZ-3 IDC or LC, loaded with 10 ng/ml peptide, in the presence of 5 ng/ml IL-7 (Strathmann Biotec). From day 17 onwards, CD8+ T cell cultures were stimulated weekly with 1x10 5 peptide-loaded JY cells, unless indicated otherwise. Two days after each restimulation, 10 U/ml IL-2 (Strathmann Biotec) was added.
One day prior to each restimulation, a sample was taken and analyzed by flow cytometry using both PE-and APC-labeled tetramers presenting the relevant epitope. Tetramer-positive CD8+ T cells were isolated by tetramer+ magnetic cell sorting and subsequently expanded. For this purpose, CD8+ T cells were weekly stimulated with irradiated feeder-mix consisting of allogeneic PBMC and JY cells in Yssel's medium supplemented with 100 ng/ml phytohaemagglutin (PHA; Murex Biotech, Dartford, U.K.) and 20 U/ml IL-2.
Intracellular IFN-γ detection
To determine the capacity of the CD8+ T cells to produce IFN-γ upon recognition of a specific target, intracellular IFN-γ staining was performed. CD8+ T cells were cultured with target cells at an effector:target cell (E:T) ratio of 2:1 in 96-well round-bottom plate in the presence of 0.5 μl of GolgiPlug (BD Biosciences). After 5 hours, cells were harvested, washed, stained with APC-labeled tetramer and PE-labeled anti-CD8 mAb. After fixation with cytofix/cytoperm solution and permeabilization with Perm/wash solution (both from BD Biosciences), cells were labeled with FITC-conjugated anti-IFN-γ Ab (BD Biosciences). Stained cells were analyzed on a FACScalibur.
Chromium Release Assay
Cytotoxic activity of CD8+ T cell lines was determined by standard chromium release assay as described (23) .
Mixed Leukocyte Reaction (MLR)
T cell stimulatory capacity of MUTZ-3 IDC and LC was determined by allogeneic MLR as described (21) .
Transwell migration assay
Chemotaxis of mature MoDC, MUTZ-3 IDC and MUTZ-3 LC was measured by migration through a polycarbonate filter of 5 μm pore size. For this purpose, 100,000 mature MoDC, MUTZ-3 IDC or MUTZ-3 LC were seeded in serum-free medium in the upper well of a 24-well transwell chamber and allowed to migrate for 4 hours towards serum-free medium alone or serum-free medium containing 250 ng/ml of the chemokines CCL19 (Peprotech) or CCL21 (Biosource International, Camarillo, CA). After 4 hours, the migrated cells were harvested and counted by flow cytometry by adding a fixed number of fluorescent flow count beads (Beckman Coulter, Galway, Ireland). The absolute number of migrated cells was expressed as: [total number of cells counted * total number of added beads] / total number of counted beads.
Cytokine release by Dendritic Cells
Immature MoDC, MUTZ-3 IDC and LC were analyzed for the release of IL-12p70, IL-10 and IL-15 as described previously (26, 29) . Briefly, for IL-12 and IL-10 production, the different DC subsets were stimulated for 8 hours in a 96-well round-bottom culture plate in IMDM + 10% FCS with either MCM mimic with or without PGE2 or the IFN/α-p-I:C type-1-polarizing cytokine cocktail, followed by a 16
hours stimulation with the CD40L-transfected J558 cell line in the presence or absence of 1000 U/ml IFN-γ (R&D systems). IL-12p70 production by MUTZ-3-IL-12 IDC and LC was determined in the absence of CD40 ligation. To do so, MUTZ-3-IL-12 IDC and LC were stimulated for 48 hours with MCM with TNF-α. After cytokine removal, cells were cultured for an additional 24 hours and supernatants were collected. For IL-15 production, the different DC subsets were stimulated for 20 hours with either MCM mimic with or without PGE2 or the IFN-α/p-I:C type-1-polarizing cytokine cocktail. Next day, the supernatants were harvested and analyzed by enzyme-linked immunosorbent assay (ELISA) to detect IL-10 (IL-10 ELISA kit; Sanquin, Amsterdam, The Netherlands), IL-12p70 and IL-15 (QuantiGlo ELISA kit, R&D systems). 
Cytokine production by MUTZ-3 IDC and LC-stimulated CD8+ and CD4+ T cells
Statistical Analysis
Differences between means of percentage of migrated dendritic cells, between means of T cell stimulatory capacity and between means of cytokine production of the different DC subsets were compared using a paired two-sided T-test. Differences between medians of percentage tetramerpositive CD8+ T cells were compared using a two-sided Mann-Whitney test. Differences were considered significant when p < 0.05.
Results
Phenotype and allogeneic T Cell Stimulatory Capacity of MUTZ-3-derived IDC and LC.
As shown in figure 1 and described previously (21) , MUTZ-3 progenitors are able to differentiate into either IDC, expressing CD1a and DC-SIGN, but lacking Langerin, or LC, expressing CD1a and Langerin, but lacking DC-SIGN ( Fig. 1A) . Upon maturation, up-regulation of co-stimulatory molecules, de novo expression of CD83 and enhanced allogeneic T cell stimulation was observed for both MUTZ-3 IDC and LC (21) . Of note, expression levels of co-stimulatory and adhesion molecules were generally higher on MUTZ-3 LC ( Fig. 1A) , which translated into a significantly higher proliferation of total PBL in an allo-MLR ( Fig. 1B ; p < 0,03). Importantly, this increased proliferation was also observed for isolated CD8β+ CTL precursors ( Fig. 1C ; p < 0,023), revealing a superior allogeneic (CD8+) T cell stimulatory capacity for MUTZ-3 LC as compared to MUTZ-3 IDC.
Lymph Node Migration Capacity of MoDC, MUTZ-3 IDC and LC.
DC are professional antigen-presenting cells with the capacity to take up antigen in the periphery and present this antigen in the secondary lymphoid organs. As described, the migration of MoDC is dependent on PGE2 (30) (31) (32) . To determine whether mature MUTZ-3 IDC and LC are capable of migrating and whether this migration is also dependent on PGE2, MUTZ-3 IDC and LC were analyzed for the expression of the chemokine receptor CCR7 by flow cytometry and for their migratory capacity towards the lymph node-homing chemokines CCL19 and CCL21 in transwell migration assays. Another important function of fully mature, immuno-stimulatory DC is the ability to produce cytokines important for T helper and cytotoxic T cell activation, like IL-12, IL-23 and IL-15 (33, 34) , whereas cytokines that play a role in the induction of T cell tolerance, such as IL-10, should preferably not be produced (35) . For that reason, CD40L-stimulated MUTZ-3 IDC, MUTZ-3 LC and MoDC were analyzed for the release of IL-12p70, IL-15, IL-23, and IL-10. Whereas MoDC released considerable amounts (ranging from 2-5 ng/ml) of IL-10 with the maturation methods employed here, no IL-10 was secreted by either MUTZ-3 IDC or MUTZ-3 LC (data not shown). MoDC also secreted higher amounts of IL-12p70 as compared to MUTZ-3 IDC, whereas MUTZ-3 LC did not secrete any detectable IL-12 ( Fig. 3A) . The IL-12p70 secretion by MoDC was impaired by the addition of PGE2 in the maturation cocktail, although this was not significant. MUTZ-3 IDC, LC and MoDC were also analyzed for the capacity to produce IL-15 and IL-23. As shown in figure 
Cytokine profile of MUTZ-3 IDC and LC-stimulated CD8+ and CD4+ T cells.
To study whether the low level or absence of IL-12p70 released by MUTZ-3 IDC and LC respectively, led to a change in cytokine production by T cells, thereby shifting T cells towards a more 
Induction of Tumor-Specific CD8+ T cells in vitro using Peptide-Pulsed HLA-A2-matched
MUTZ-3 IDC or MUTZ-3 LC.
DC exhibit the unique capacity to induce and activate tumor-specific CTL both in vivo and in vitro.
We previously described that MUTZ-3 IDC can be used for in vitro priming and expansion of functional TAA-specific effector CTL and that the efficiency of this induction was comparable to autologous peptide-loaded MoDC (22) . In order to determine whether MUTZ-3 LC were also capable of inducing functional tumor-specific CTL and to see whether the CTL induction efficiency is comparable to that of MUTZ-3 IDC, both IDC and LC were used as stimulator cells in an in vitro CTL induction protocol. To this end, HLA-A2+ CD8β+ CTL precursors were stimulated with HLA-A2-matched and peptide-loaded mature MUTZ-3 IDC and MUTZ-3 LC in multiple parallel cultures starting with 1x10 6 CD8β+ CTL precursors in each culture. Epitopes selected were the immunodominant HLA-A2-restricted MART-1derived peptide MART-1 26L , the CEA-derived peptide CEA 571 , the Her-2/neu-derived peptide Her-2/neu 369 and the PSA-derived epitope PSA 146 . From the second round of stimulation onwards, the presence of tumor-specific CD8+ T cells was monitored by tetramer staining. When stimulated with MUTZ-3 IDC significantly higher levels of MART-1 26L -tetramer-positive T cells could be detected after two IVS compared to MUTZ-3 LC in two of three donors analyzed (Fig. 4A ). In addition, a similar trend was also observed for the adenocarcinoma-associated peptides CEA 571 , PSA 146 and Her-2/neu 369 , in number of tetramer-positive cultures (17/48 versus 9/48 individual cultures for MUTZ-3 IDC and LC respectively), as well as in higher detectable maximum tetramer-positive T cell frequencies (Fig. 4B ), although these differences did not reach statistical significance. 
CD8β+ T cells and CD8β
-PBMC were cultured for 7 days with either medium (unstimulated) or MCM mimic + PGE2-matured MUTZ-3 IDC or LC, followed by a four hour stimulation with PMA and ionomycin and analyzed for the production of IL-4 and IFN-γ.
Percentage of IFN-γ+ and IL-4+ cells were gated for live CD3+/CD8+ or live CD3+/CD4+ T cells. Data represent the means ± SEM of 4 independent experiments of CD8+ T cells (left panel) and CD4+ T cells (right panel). Differences between means of IL-12p70 and IL-15
production of the different DC subsets and between means of percentage of IFNγ and or IL-4 production of MUTZ-3 IDC and LC-stimulated T cells were compared using a paired twosided T-test and were considered significant when p < 0.05, as indicated with an asterisk (*).
igure 4. Flow cytometric HLA-A2+ tetramer (Tm)-binding and functional analysis of MUTZ-3
As described, type-1 T cell stimulatory cytokines such as IL-12 are important in functional T cell p 26L Although functionally active, functional avidity of the MUTZ-3 IDC and LC-generated MART-1 26L -and Her-2/neu 369 -specific CD8+ T cells were relatively low. Both MUTZ-3 IDC and LC-generated MART-1 26L -and Her-2/neu 369 -specific CD8+ T cells were able to recognize exogenously loaded MART-1 26Land Her-2/neu 369 target cells respectively, but recognition of endogenously processed and presented MART-1 26L and Her-2/neu 369 on tumor cells was low, as analyzed by intracellular IFN-γ ( Fig. 4C ) and 51 chromium release assays (Fig. 4D ). 
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MART-1 26 % tetramer-+ T cells MART-1 26 MART-1 26 10/10 10/ fig. 5B; open symbols) , MUTZ-3-IL-12 IDC and LC-generated MART-1 26L -specific CD8+ T cells exhibited high functional avidity ( fig. 5B, closed symbols) . The increased functional avidity of the MUTZ-3-IL-12 IDC and IL-12 LC-generated CD8+ T cells resulted in an increased capacity to recognize endogenously expressed MART-1 26 on tumor cells as measured by intracellular IFN-γ ( Fig.   5C ) and 51 chromium release assay (Fig. 5D) . Indeed, MUTZ-3-IL-12 IDC (data not shown) and IL-12 LC-generated MART-1 26L -specific CD8+ T cells (Fig 5D; right panel) were both able to specifically recognize and kill the HLA-A2+/MART-1+ tumor cell line Mel-AKR, whereas MUTZ-3 IDC (not shown) and LC-generated MART-1 26L -specific CD8+ T cells ( Fig. 5D; left panel) were not. In addition, MART-1 26L -specific CD8+ T cells induced with MUTZ-3-IL-12 IDC/LC also showed a reduced expression of CD27, CD28, CD62L and CCR7 compared to MUTZ-3 IDC/LC stimulated MART-1 26L -specific CD8+ T cells, indicative of a more advanced effector T cell differentiation (data not shown).
In summary, in vitro functions of IDC and LC suggest that both DC subsets can serve as valid vaccine vehicles for tumor immunotherapy, particularly after provision of type-1 T cell stimulatory cytokines.
Discussion
Because of their critical role in orchestrating the immune response, dendritic cells are increasingly applied as vaccines for the treatment of cancer (17) . So far, in the majority of clinical trials, MoDC have been used for vaccination. However, it has been described recently that CD34-derived LC exhibit superior T cell priming capacity over CD34-derived IDC and MoDC in vitro, suggesting a potential benefit of the use of LC in clinical DC vaccination. In this study, extensive characterization of the functional differences between IDC and LC was performed by making use of the MUTZ-3 cell line as a model system. We show here that both DC subsets are capable of inducing anti-tumor T cell immunity and provide valid vaccine vehicles for tumor immunotherapy, albeit that provision of IL-12p70 is required to ensure optimal T cell stimulation. As described previously, employing allogeneic MUTZ-3 IDC as stimulator cells in an in vitro induction protocol, functional tumor-specific CTL could be generated (22) .
In this study, by employing the same method, we confirmed previous findings of the applicability of allogeneic HLA-A2-matched MUTZ-3 IDC. Although mature LC showed significantly higher allogeneic T cell stimulatory capacity, IDC supported the induction of tumor antigen-specific CD8+ T cells at an overall higher efficiency as compared to LC. This was not in line with findings from other groups, demonstrating superior CTL priming capacity of CD34-derived LC over CD34-derived IDC or MoDC (15, 19) . Discrepancies might be explained by the fact that we made use of an allogeneic T cell activation system. Indeed, the observed enhanced allogeneic T cell stimulatory capacity of MUTZ-3 LC, as compared to MUTZ-3 IDC, may account for the decreased CTL priming capacity, with possible preferential outgrowth of non-specific T cells. Of note, comparing the induction efficiency of autologous MoDC and allogeneic MUTZ-3 IDC (22), we previously did not find evidence for this allogeneic response interfering with the antigen-specific CTL response. Moreover, introducing IL-12p70 also resulted in a more advanced effector T cell differentiation with enhanced functional avidity and tumor cell recognizing abilities of the IDC and LC generated CD8+ T cells, as also recently described by us using mRNA-transfected MoDC (36) .
The low level or absence of pro-inflammatory cytokine production by MUTZ-3 IDC and LC as compared to MoDC might be explained by the leukemic origin of the MUTZ-3 cell line, since AMLblast-derived DC are described to produce only low amounts of IL-12 (37) . However, the observation that MUTZ-3 IDC and LC do not produce any IL-10 with the maturation cocktails employed in this study, argues against a possible immunosuppressive phenotype. Moreover, the low level or absence of IL-12p70 production is consistent with recently described findings that skin-migrated IDC and LC, as well as CD34-derived IDC and LC, also do not produce IL-12p70 (19, 38, 39) .
A pivotal role of fully mature, immuno-stimulatory DC is the ability of DC to migrate to the draining lymph nodes. Upon maturation, CCR7 expression was induced on MUTZ-3 IDC and LC and this expression was accompanied by responsiveness to lymph node-homing chemokines CCL19 and CCL21. Interestingly, and unlike migration of MoDC (30, 31) , migration of MUTZ-3 IDC and LC was independent (IDC) or less dependent (LC) on PGE2. Importantly, so far it is not clear whether CD34derived IDC or LC migration is dependent on PGE2. Of note, PGE2 dependence for MoDC migration could be confirmed in our experiments, thereby validating our migration assay. Furthermore, the particular high migration of MUTZ-3 IDC in response to CCL19 and CCL21 upon maturation with the IFN-α/p-I:C-type-1 cocktail also underlines this PGE2-independence (26) . Since PGE2 has been described as an inflammatory mediator with a Th2 driving role (40, 41) , the ability of MUTZ-3 IDC and LC to migrate independent of PGE2 towards lymph node homing chemokines might be beneficial in clinical DC vaccination settings.
Taken together, comparative functional analysis of MUTZ-3 derived IDC and LC revealed that, except for the inability of LC to release distinct type-1 T cell stimulatory cytokines, both DC subsets exhibit functional properties that are essential for the in vivo generation of CTL mediated immunity. In conclusion, both DC subsets are valid vaccine vehicles for tumor immunotherapy, but provision of type-1 T cell stimulatory cytokines such as IL-12p70 may be required to ensure optimal T cell stimulation.
Addendum: data added in proof
In response to reviewers' comments about verifying the abovementioned findings in a more physiological setting, we decided to analyze allogeneic and tumor antigen-specific T cell stimulatory properties and the LN migratory potential of human skin-derived DDC and LC.
Materials and Methods:
Isolation of Dermal Dendritic Cells and Langerhans Cells from Skin
Human HLA-A2 + skin specimens were obtained from healthy donors undergoing corrective breast or abdominal plastic surgery after informed consent. 3-mm thick slices of skin containing both the epidermis and the dermis were cut by use of a dermatome. Slices of skin were cut in pieces of 1 cm2 and incubated with 2.4 U/ml Dispase II (Roche Diagnostics, Mannheim, Germany) for 30 minutes at 37ºC. The epidermis and dermis were separated with tweezers and subsequently (separately) cultured in IMDM complete medium supplemented with 1000 U/ml GM-CSF and 10 ng/ml IL-4 for 48 hours, after which the epidermal and dermal sheets were removed. After 48-72 hours, epidermis-and dermis-migrated cells were harvested, counted, and % CD1a+ cells within these populations was determined by flow cytometry.
Phenotypic and functional analysis of skin-emigrated DDC and LC.
Phenotype of epidermis-and dermis-emigrated DDC and LC was analyzed by flow cytometry. For further functional analysis, the amount of DDC/LC used was calculated based on the expression of the pan-skin DC marker CD1a. Allogeneic T cell stimulatory capacity was determined by MLR as described above. Lymph node-homing capabilities of skin-emigrated DDC and LC was determined by transwell migration assay. To this end, 25,000 skin-emigrated DDC and LC were allowed to migrate towards serum-free medium alone or serum-free medium containing 250 ng/ml of the chemokines CCL19 or CCL21. After 18 hours, the percentage of migrated CD1a+ DDC and LC was determined by fluorescent flow count bead-mediated counting on a flow cytometer. In vitro tumor-specific CTLinducing capabilities of skin-emigrated DDC and LC was determined as described above, with some minor modifications. In brief, multiple bulk cultures of 1x10 6 CD8β+ T precursors were cultured with 5x10 4 MART-1 26L peptide-loaded CD1a+ skin DDC or LC and with 1x10 6 irradiated (80 Gy) CD8βautologous PBMC in Yssel's medium supplemented with 1% hAB serum (ICN Biochemicals), 10 ng/ml IL-6 and 10 ng/ml IL-12 in a 24 well tissue-culture plate. At day 1, 10 ng/ml IL-10 (R&D Systems, Minneapolis, MN) was added. After 10 days, CD8+ T cell cultures were analyzed for the presence of MART-1 26L -specific CD8+ T cells by tetramer staining.
Results and Discussion
Analysis of T cell stimulatory properties of human skin-derived DDC and LC
Human skin-emigrated DDC and LC were analyzed for the expression of co-stimulatory and adhesion molecules, their allogeneic and tumor antigen-specific stimulatory capacity and their LN migratory potential. DDC and LC were obtained from human skin samples by active migration from dermal and epidermal sheets. As described previously by us (42) MoDC (15, 19) . Whereas for MUTZ-3 IDC and LC this discrepancy could be explained by the observed enhanced allogeneic T cell stimulatory capacity of MUTZ-3 LC as compared to MUTZ-3 IDC ( figure 1B and C), possibly resulting in preferential outgrowth of non-specific T cells, our data clearly show that this cannot explain the observed differences in CTL priming efficiency by primary skin-derived DDC and LC ( figure 6B ). Alternatively, differences in CTL priming potential might be related to differences in the production of pro-inflammatory cytokines as also described for CD34-derived IDC and LC (19) .
Similarly, primary skin-derived LC have been reported to be deficient in IL-12 production (43, 44) . To ascertain the precise roles of such cytokines in CTL priming by primary LC and DDC, additional investigations are required. Of note, functional avidity analysis revealed no significant difference in functional activity between the skin DDC-and LC-generated MART-1 26L -specific CD8+ T cells ( figure   6E ).
In summary, the relative CD8+ T cell induction capacities of skin-derived primary DDC and LC accurately reflect our findings for MUTZ-3 IDC and LC, further validating the MUTZ-3 as a human DDC/LC-equivalent cell line model and demonstrating that both DC subsets can serve as valid vaccine vehicles for tumor immunotherapy. . Functional activity of skin DDC and LC-generated CD8+ T cells was determined by intracellular IFNγ assay. Target cells used were HLA-A2+ JY cells loaded with serial 10-fold dilutions of MART-1 26L peptide. Differences between means of T cell stimulatory capacity, between means of percentage migrated cells and between means of percentage tetramer-positive CD8+ T cells were compared using a two-sided t-test and were considered significant when p < 0.05.
